-16.9%
CRDO vs GSK
+14.9%
-31.8%
-54.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -9.5% | +5.0% | -14.6% | -5.6% |
| 7D | -21.4% | +4.9% | -26.4% | -18.0% |
| 30D | -35.8% | +9.9% | -45.6% | -30.4% |
| 3M | -42.6% | +0.2% | -42.8% | -40.8% |
| 6M | -24.2% | +2.3% | -26.5% | -20.3% |
| YTD | -5.1% | +7.1% | -12.2% | +6.4% |
| 1Y | -16.9% | +13.1% | -30.0% | -6.1% |
| All | -16.9% | +14.9% | -31.8% | -6.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling